Clinical Research Directory
Browse clinical research sites, groups, and studies.
Plasma Neprilysin for Predicting Sepsis Within 48 Hours in ICU Patients With Infection or Suspected Infection
Sponsor: Zhujiang Hospital
Summary
The goal of this multicenter prospective observational cohort study is to determine whether plasma neprilysin can predict the development of sepsis within 48 hours in adults admitted to an intensive care unit with confirmed or suspected infection who do not have sepsis at enrollment. The study will be conducted at Zhujiang Hospital, Southern Medical University, and Guangzhou First Municipal People's Hospital. Plasma samples remaining after routine clinical testing will be used to measure neprilysin and conventional sepsis biomarkers. Sublingual microcirculation will also be assessed when feasible. Participants will be assessed for the development of sepsis from enrollment through 48 hours and will be followed for survival through Day 28. No treatment or clinical intervention will be assigned by the study protocol.
Official title: Plasma Neprilysin for Early Prediction of Sepsis Within 48 Hours in ICU Patients With Infection or Suspected Infection (NEPSIS): A Multicenter Prospective Cohort Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
488
Start Date
2026-08-01
Completion Date
2028-04-30
Last Updated
2026-09-01
Healthy Volunteers
No
Interventions
Plasma Neprilysin Measurement
Plasma collected at enrollment will be tested for neprilysin using an enzyme-linked immunosorbent assay. The result will not be used to guide clinical treatment.
Conventional Sepsis Biomarker Measurement
Plasma will be batch-tested for interleukin-6, C-reactive protein, and procalcitonin for comparison with plasma neprilysin.
Sublingual Microcirculation Assessment
Sublingual microcirculation will be assessed when oral conditions permit. Measurements will include microvascular flow index, perfused vessel density, and perfused boundary region. The results will not be used to assign treatment.
Locations (2)
Guangzhou First People's Hospital
Guangzhou, Guangdong, China
Department of Critical Care Medicine of Zhujiang Hospital,Southern Medical University
Guangzhou, Guangdong, China